Target intelligence / Profile preview

Solute carrier family 35 member G2 (SLC35G2)

Target
SLC35G2
Molecular classification
Transporter, Transmembrane protein, SLC (Solute Carrier) family, EamA drug/metabolite transporter-like family
01

Overview

Solute carrier family 35 member G2 (SLC35G2), also known as transmembrane protein 22 (TMEM22), is a polytopic transmembrane protein belonging to the SLC35 family of nucleotide sugar transporters, specifically recognized as an EamA drug/metabolite transporter-like protein with two EamA domains. It is predominantly localized to the endoplasmic reticulum, Golgi apparatus, endosomes, and lysosomes, where it is believed to contribute to the transport of nucleotide sugars, supporting glycoprotein formation and potentially participating in cellular homeostasis. SLC35G2 is differentially regulated in cancers such as renal cell carcinoma, with evidence that its expression may be involved in tumor progression and its silencing can diminish cell growth. Although not yet definitively linked to interacting drugs or safety challenges, its expression profile suggests a potential as a novel cancer biomarker and future therapeutic target.

Other names
TMEM22MGC3295DKFZp564K2464Transmembrane protein 22solute carrier family 35 member G2transmembrane protein 22
02

Biological functions

Nucleotide-sugar transportGlycoprotein synthesisPotential roles in protein post-translational modification and cellular homeostasis
03

Disease associations

Cancer (renal cell carcinoma, cholangiocarcinoma, melanoma)Possible involvement in tumor progression
04

Biomarkers

Differential expression in several cancers (up-regulated in renal cell carcinoma and patient PBMCs post-nephrectomy)potential as a cancer biomarker (requires further validation)

Beyond the preview

Go deeper on Solute carrier family 35 member G2 (SLC35G2).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Solute carrier family 35 member G2 (SLC35G2).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call